- Eli Lilly press release (NYSE:LLY): Q2 Non-GAAP EPS of $2.11 beats by $0.11.
- Revenue of $8.31B (+28.0% Y/Y) beats by $700M.
- New Products contributed $1.00 billion to revenue in Q2 2023, led by Mounjaro. Growth Products revenue increased 16% to $4.93 billion in Q2 2023, led by Verzenio, Jardiance and Taltz.
- The effective tax rate on a non-GAAP basis was 16.1% in Q2 2023 compared with 14.2% in Q2 2022.
-
Outlook: 2023 reported EPS guidance raised $1.02 to the range of $9.20 to $9.40 and non-GAAP EPS guidance raised $1.05 to the range of $9.70 to $9.90 vs. consensus of $8.75.